Skip to main content

Advertisement

Table 2 Comparison of characteristics of breast cancer among patients aged 50–69 years between organised and opportunistic mammography screening. Fribourg cancer registry 2006–2014

From: Comparison between opportunistic and organised breast cancer mammography screening in the Swiss canton of Fribourg

  Organised screening Number (%) Opportunistic screening Number (%) ORa CI95%a P-value
Type
 In situ 72 (18.0) 22 (10.7) 1 [1.09; 3.02] 0.022
 Invasive 330 (82.1) 183 (89.3) 1.8
Tumour sizeb
  ≤ 20 mm 253 (77.8) 145 (80.6) 1 [0.54; 1.33] 0.476
  > 20 mm 72 (22.2) 35 (19.4) 0.8
T stageb
 T1mic-T1a 33 (10.2) 26 (14.4) 1 [0.36; 1.19] 0.518
 T1b 85 (26.2) 45 (25.0) 0.7 [0.39; 1.25]
 T1c 135 (41.5) 74 (41.1) 0.7 [0.32; 1.19]
 T2-T3 72 (22.2) 35 (19.4) 0.6  
N stageb
 N0 252 (77.1) 134 (75.3) 1 [0.72; 1.69] 0.652
 N+ 75 (22.9) 44 (24.7) 1.1
Metastasisb
 M0 326 (98.8) 176 (97.8) 1 [0.46; 7.50] 0.387
 M1 4 (1.2) 4 (2.2) 1.9
Histological subtype b
 Ductal, NST 245 (74.2) 133 (72.7) 1 [0.32; 1.72] 0.543
 Ductal, others 20 (6.1) 8 (4.4) 0.7 [0.60; 1.77]
 Lobular 43 (13.0) 24 (13.1) 1.0 [0.78; 2.91]
 Mixed 22 (6.7) 18 (9.8) 1.5  
Molecular subtype b,c
 Luminal A 160 (53.5) 83 (53.5) 1   0.440
 Luminal B, HER2- 75 (25.1) 36 (23.2) 0.9 [0.57; 1.49]  
 Luminal B, HER2+ 20 (6.7) 8 (5.2) 0.8 [0.33; 1.83]  
 HER2+, non-luminal 11 (3.7) 12 (7.7) 2.1 [0.89; 8.97]  
 Triple negative 33 (11.0) 16 (10.3) 0.9 [0.49; 1.80]  
ER/PR b,c
 ER+/PR+ 259 (78.5) 143 (78.5) 1 [0.40; 1.64] 0.693
 ER+/PR- 27 (8.2) 12 (6.6) 0.8 [0.69; 1.93]
 ER−/PR- 44 (13.3) 28 (15.3) 1.2  
MIB-1 b,c
  < 15% 172 (59.1) 92 (62.2) 1 [0.59; 1.32] 0.537
  ≥ 15% 119 (40.9) 56 (37.8) 0.9
HER2b
 Positive 31 (9.5) 20 (11.0) 1 [0.47; 1.54] 0.595
 Negative 295 (90.5) 162 (89.0) 0.9
  1. aCalculated by logistic regression (reference: organised screening);
  2. bOR odds ratio, CI confidence interval;
  3. cInvasive breast cancer only;
  4. dER estrogen receptor, PR progesteron receptor, HER2 gene overexpression, MIB-1 proliferation rate